US9782342B2ActiveUtilityA1

Composite magnetic nanoparticle drug delivery system

65
Assignee: ASMATULU RAMAZANPriority: Oct 11, 2010Filed: Oct 11, 2011Granted: Oct 10, 2017
Est. expiryOct 11, 2030(~4.2 yrs left)· nominal 20-yr term from priority
Inventors:Ramazan AsmatuluHeath Edward MisakShang-You YangPaul Hastings Wooley
A61P 35/00A61K 9/5094A61P 29/00A61K 9/0009A61K 9/5031
65
PatentIndex Score
4
Cited by
7
References
24
Claims

Abstract

A composite magnetic nanoparticle drug delivery system provides targeted controlled release chemotherapies for cancerous tumors and inflammatory diseases. The magnetic nanoparticle includes a biocompatible and biodegradable polymer, a magnetic nanoparticle, the biological targeting agent human serum albumin, and a therapeutic pharmaceutical composition. The composite nanoparticles are prepared by oil-in-oil emulsion/solvent evaporation and high shear mixing. An externally applied magnetic field draws the magnetic nanoparticles to affected areas. The biological targeting agent draws the nanoparticles into the affected tissues. Polymer degradation provides controlled time release delivery of the pharmaceutical agent.

Claims

exact text as granted — not AI-modified
We claim: 
     
       1. A method of localized therapy including the steps of: providing a quantity of composite nanoparticles comprising a synthetic resin polymer composition, magnetic nanoparticles, a biological targeting component that draws the composite nanoparticles into tissue, and a pharmaceutical composition, positioning magnets adjacent an area of a patient to be treated, delivering a quantity of the composite nanoparticles into the body of the patient, and magnetically drawing the composite nanoparticles to the affected area, wherein said biological targeting component that draws the composite nanoparticles into tissue is albumin. 
     
     
       2. The method of localized therapy of  claim 1 , wherein a quantity of 10 4  to 10 5  composite magnetic nanoparticles is delivered into the body of a patient by injection into the bloodstream. 
     
     
       3. The method of  claim 1 , wherein the amount of biological targeting component that draws the composite nanoparticles into tissue in the composite nanoparticles comprises from about 5% to about 85% (v/v). 
     
     
       4. The method of  claim 3 , wherein said synthetic resin polymer is biodegradable. 
     
     
       5. The method of  claim 3 , wherein said synthetic resin polymer is selected from the group consisting of poly(lactic-co-glycolic acid) or poly(D,L-lactide-co-glycolide) (or PLGA), chitosan, poly(lactic acid) (or PLA), poly(glycolic acid) (or PGA), polycaprolactone (or PCL), and combinations thereof. 
     
     
       6. The method of  claim 5 , wherein said synthetic resin polymer is PLGA. 
     
     
       7. The method of  claim 6 , wherein said PLGA is made up of monomers and each monomer is present in an amount ranging from 15% to about 85%. 
     
     
       8. The method of  claim 1 , wherein said composite nanoparticles include from about 5% to about 95% (w/v) of said synthetic resin polymer. 
     
     
       9. The method of  claim 1 , wherein said pharmaceutical composition is selected from the group consisting of anti-rheumatic agents (DMARDs), anti-inflammatory agents, anti-malarial medications, biological response modifiers, corticosteroids, cyclooxygenase-2 (COX-2) inhibitors, methotrexate, 5-Fluorouracil, doxorubicin, epirubicin, cyclophosphamide, docetaxel, doxorobicin, paclitaxel, cisplatin, and combinations thereof. 
     
     
       10. The method of  claim 1 , wherein said magnetic nanoparticle is selected from the group consisting of magnetite and cobalt ferrite. 
     
     
       11. The method of  claim 1 , wherein said composite magnetic nanoparticles include from about 0.5% to about 50% of said magnetic nanoparticles. 
     
     
       12. The method of  claim 1 , wherein said magnetic nanoparticles have a diameter of from about 5 nm to about 20 nm. 
     
     
       13. The method of  claim 1 , wherein said composite nanoparticle has an average diameter from about 40 nm to about 1.1 μm. 
     
     
       14. A method of localized therapy including the steps of: providing a quantity of composite nanoparticles comprising a biodegradable synthetic resin polymer composition selected from the group consisting of poly(lactic-co-glycolic acid) or poly(D,L-lactide-co-glycolide) (or PLGA), chitosan, poly(lactic acid) (or PLA), poly(glycolic acid) (or PGA), polycaprolactone (or PCL), and combinations thereof, magnetic nanoparticles, a biological targeting component that draws the composite nanoparticles into tissue, and a pharmaceutical composition, positioning magnets adjacent an area of a patient to be treated, delivering a quantity of the composite nanoparticles into the body of the patient, and magnetically drawing the composite nanoparticles to the affected area, wherein said biological targeting component that draws the composite nanoparticles into tissue is albumin. 
     
     
       15. The method of  claim 14 , wherein the amount of albumin in the composite nanoparticles comprises from about 5% to about 85% (v/v). 
     
     
       16. The method of  claim 14 , wherein said biodegradable synthetic resin polymer is PLGA. 
     
     
       17. The method of  claim 14 , wherein said pharmaceutical composition is selected from the group consisting of anti-rheumatic agents (DMARDs), anti-inflammatory agents, anti-malarial medications, biological response modifiers, corticosteroids, cyclooxygenase-2 (COX-2) inhibitors, methotrexate, 5-Fluorouracil, doxorubicin, epirubicin, cyclophosphamide, docetaxel, doxorobicin, paclitaxel, cisplatin, and combinations thereof. 
     
     
       18. The method of  claim 14 , wherein said magnetic nanoparticle is selected from the group consisting of magnetite and cobalt ferrite. 
     
     
       19. The method of  claim 14 , wherein said composite magnetic nanoparticles include from about 0.5% to about 50% of said magnetic nanoparticles. 
     
     
       20. The method of  claim 14 , wherein said magnetic nanoparticles have a diameter of from about 5 nm to about 20 nm. 
     
     
       21. The method of  claim 14 , wherein said composite nanoparticle has an average diameter from about 40 nm to about 1.1 μm. 
     
     
       22. The method of  claim 14 , wherein a quantity of 10 4  to 10 5  composite magnetic nanoparticles is delivered into the body of a patient by injection into the bloodstream. 
     
     
       23. The method of  claim 16 , wherein said PLGA is made up of monomers and each monomer is present in an amount ranging from 15% to about 85%. 
     
     
       24. The method of  claim 14 , wherein said composite nanoparticles include from about 5% to about 95% (w/v) of said biodegradable synthetic resin polymer.

Join the waitlist — get patent alerts

Track US9782342B2 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.